Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 12,000 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total transaction of $168,240.00. Following the transaction, the general counsel now directly owns 105,386 shares in the company, valued at $1,477,511.72. This trade represents a 10.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Centessa Pharmaceuticals Stock Performance
NASDAQ:CNTA traded up $0.09 during trading hours on Friday, hitting $13.13. 817,525 shares of the company were exchanged, compared to its average volume of 733,874. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -7.25 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $8.46 and a 52-week high of $19.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The company's 50 day moving average price is $12.83 and its 200-day moving average price is $14.72.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.
Institutional Trading of Centessa Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd lifted its stake in Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Centessa Pharmaceuticals during the 1st quarter valued at approximately $47,000. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Centessa Pharmaceuticals during the 1st quarter valued at approximately $147,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on CNTA shares. Morgan Stanley restated an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target on the stock. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Finally, Guggenheim restated a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.89.
Read Our Latest Analysis on Centessa Pharmaceuticals
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Recommended Stories

Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.